A new, compact synthesizer of PET radiotracers -- about a third the size of systems currently available -- is poised to enter the U.S. market later this year. Hear an interview with its inventor, Maxim Kiselev, Ph.D., vice president of R&D for IBA Molecular.
A new, compact synthesizer of PET radiotracers - about a third the size of systems currently available - is poised to enter the U.S. market later this year. Synthera, developed by IBA (Ion Beam Applications) Molecular and priced at about $96,000, was unveiled at the Society of Nuclear Medicine meeting June 3 to 7 in San Diego. Its core component, the ejectable Integrated Fluidic Processor, makes it a true multirun system capable of producing various radiotracers, including FDG, according to its inventor, Maxim Kiselev, Ph.D., vice president of R&D for IBA Molecular. (hear a two-minute interview with Kiselev from the SNM exhibit floor)
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.